A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : BCNU

Search Conditions:
Search Keyword : BCNU
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: BCNU
Appearance Frequency: 906 time(s)
Long forms: 48

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
1,3-bis(2-chloroethyl)-1-nitrosourea
(845 times)
Neoplasms
(334 times)
MGMT (36 times)
CCNU (31 times)
BSO (29 times)
1965 IN VIVO ANTIVIRAL ACTIVITY OF 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA.
BACKGROUND: Carmustine
(4 times)
Magnetic Resonance Imaging
(1 time)
ep-MRI (1 time)
ep-T2-HIAs (1 time)
HGG (1 time)
1990 Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
biodegradable carmustine
(4 times)
Neoplasms
(2 times)
IL-12 (1 time)
KPS (1 time)
MRI (1 time)
2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
bis-chloroethyl-nitrosurea, carmustine
(3 times)
Neoplasms
(1 time)
LEFCT-EC (1 time)
2005 Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
Bacterial controlled nursing units
(2 times)
General Surgery
(1 time)
--- 1977 The contribution of a bacterially isolated environment to the prevention of infection in seriously burned patients.
beam radiotherapy, and carmustine
(2 times)
Radiotherapy
(1 time)
ASTRO (1 time)
ESTRO (1 time)
2002 The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
bifunctional alkylators, including carmustine
(2 times)
Molecular Biology
(1 time)
MMR (2 times)
TMZ (2 times)
Mel (1 time)
2008 Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
both carmustine
(2 times)
Neoplasms
(2 times)
CPA (1 time)
GST (1 time)
LD10 (1 time)
1989 Toxicity of intraperitoneally administered antitumour drugs in athymic rats.
caused by carmustine
(2 times)
Neoplasms
(1 time)
i.p (1 time)
MDA (1 time)
TMZ (1 time)
1988 Cell-cycle, phase-specific cell killing by carmustine in sensitive and resistant cells.
10  N-nitroso-1,3-bis-(2-chloroethyl)urea
(2 times)
General Surgery
(2 times)
--- 1984 [Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperthermia].
11  BACKGROUND: Intra-arterial chemotherapy with carmustine
(1 time)
Neoplasms
(1 time)
BTCG (1 time)
CT (1 time)
1995 Evaluating glioma therapies: modeling treatments and predicting outcomes.
12  BACKGROUND: Local delivery of carmustine
(1 time)
Neoplasms
(1 time)
DOX (1 time)
GBM (1 time)
2005 Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.
13  BACKGROUND: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine
(1 time)
Neoplasms
(1 time)
AUC (1 time)
1993 Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
14  BACKGROUND: We have reported that carmustine
(1 time)
Medicine
(1 time)
PCV (1 time)
2005 Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
15  based on a combination regimen with carmustine
(1 time)
Brain
(1 time)
MTX (1 time)
PB (1 time)
PHT (1 time)
1983 Decreased phenytoin level during antineoplastic therapy: a case report.
16  BCNU administered
(1 time)
Pathology
(1 time)
LPO (1 time)
1999 Cytoprotective effects of trimetazidine in carmustine cholestasis.
17  BCNU therapy in R
(1 time)
Diagnostic Imaging
(1 time)
ADC (1 time)
SI (1 time)
2006 Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
18  BCNU were determined and plasma AUC
(1 time)
Transplantation
(1 time)
HDCT (1 time)
PBPC (1 time)
1998 High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
19  BEAM regimen consisting of carmustine
(1 time)
Hematology
(1 time)
auto-HSCT (1 time)
Mel (1 time)
OS (1 time)
2016 Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
20  been reported that the toxicity of carmustine
(1 time)
Drug Therapy
(1 time)
ALDH1 (1 time)
CEPM (1 time)
CY (1 time)
2001 Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine.
21  been used in testing other active agents such as carmustine
(1 time)
Neoplasms
(1 time)
CT (1 time)
MRI (1 time)
SWOG (1 time)
1991 Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
22  being treated with carmustine
(1 time)
Medicine
(1 time)
--- 1980 Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
23  bendamustine replacing carmustine
(1 time)
Hematology
(1 time)
ASCT (1 time)
BeEAM (1 time)
CR (1 time)
2017 A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
24  benefit for chemotherapy using carmustine
(1 time)
Neoplasms
(1 time)
Ara-C (1 time)
KPS (1 time)
2003 Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
25  beta-hydroxybutyric acid and anticancer agents: carmustine
(1 time)
Chemistry
(1 time)
GBM (1 time)
MCT1 (1 time)
SLN (1 time)
2021 Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture.
26  better than that of carmustine
(1 time)
Biochemistry
(1 time)
AO/EB (1 time)
AP (1 time)
DAPI (1 time)
2013 Synergistic anti-glioma effect of Hydroxygenkwanin and Apigenin in vitro.
27  between anticancer drugs such as carmustine
(1 time)
Neurology
(1 time)
P-gp (1 time)
PCB (1 time)
VCR (1 time)
2000 The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme.
28  between carmustine
(1 time)
Antineoplastic Agents
(1 time)
CI (1 time)
rhTNF alpha (1 time)
TNF (1 time)
1992 A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.
29  between GAT and carmustine
(1 time)
Biochemistry
(1 time)
CENU (1 time)
1988 Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides.
30  bifunctional alkylating agents carmustine
(1 time)
Neoplasms
(1 time)
--- 1992 Enhancement of alkylating agent activity in vitro by PD 128763, a potent poly(ADP-ribose) synthetase inhibitor.
31  Bifunctional alkylating agents, such as chlorambucil or carmustine
(1 time)
Biochemistry
(1 time)
1-meA (1 time)
3-meC (1 time)
ICLs (1 time)
2004 Alkylation damage in DNA and RNA--repair mechanisms and medical significance.
32  biodegradable wafers impregnated with carmustine
(1 time)
Nervous System Neoplasms
(1 time)
VIGILANT (1 time)
2017 Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.
33  bleomycin, cisplatin, cyclophosphamide and bischloroethylnitosurea
(1 time)
Genetics
(1 time)
SCE (1 time)
2003 Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics.
34  blood flow within the middle cerebral artery during 1.3-bis(2-chlorethyl)nitrosurea
(1 time)
Radiology
(1 time)
--- 1986 Transcranial Doppler monitoring of blood flow in the middle cerebral artery during angiography and drug perfusion.
35  bone marrow cells for carmustine
(1 time)
Antineoplastic Agents
(1 time)
CFE (1 time)
CFU-GM (1 time)
1994 Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
36  bone marrow transplantation (HDCT/ABMT) with cyclophosphamide, etoposide, and carmustine
(1 time)
Neoplasms
(1 time)
Dexa-BEAM (1 time)
HDCT/ABMT (1 time)
WHO (1 time)
1994 Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
37  border, and chemotherapy with nitrosourea
(1 time)
Neurology
(1 time)
CT (1 time)
2000 Long-term survival in a patient with supratentorial glioblastoma: clinical considerations.
38  both diamide, which is an oxidant of GSH, and 1,3bis(2-chlorethyl)-1-nitrosourea
(1 time)
Ophthalmology
(1 time)
TM (1 time)
1983 Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility.
39  brain tumor cases in the pre-Carmustine
(1 time)
Brain
(1 time)
FS (1 time)
IOD (1 time)
PS (1 time)
2014 Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
40  brain tumors following the administration of cisplatin and carmustine
(1 time)
Medicine
(1 time)
--- 1989 Decreased phenytoin levels in patients receiving chemotherapy.
41  brain tumors was correlated with resistance to carmustine
(1 time)
Neoplasms
(1 time)
--- 1996 Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
42  breast carcinoma resistant to the common treatment regimens, vindesine, carmustine
(1 time)
Neoplasms
(1 time)
--- 1982 [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
43  breathing, and carmustine
(1 time)
Neoplasms
(1 time)
--- 1988 Potentiation of rat brain tumor therapy by fluosol and carbogen.
44  Bu instead of carmustine
(1 time)
Hematology
(1 time)
ASCT (1 time)
Bu (1 time)
PTCLs (1 time)
2020 Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
45  Bulk quantities and pharmaceutical preparations of the antineoplastic drugs carmustine
(1 time)
Pharmacology
(1 time)
PCNU (1 time)
1989 Degradation and disposal of some antineoplastic drugs.
46  Busulfan, carmustine
(1 time)
Antineoplastic Agents
(1 time)
VOD (1 time)
1995 High-dose chemotherapy regimens for solid tumors.
47  compounds--1,3-bis(2-chloroethyl)-1-nitrosourea
(1 time)
Neurosurgery
(1 time)
CCNU (1 time)
1982 Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
48  R3L6-BCNU had the highest transfection at a 0.8:1 weight ratio
(1 time)
Biochemistry
(1 time)
pDNA (1 time)
PLL (1 time)
R3L6 (1 time)
2011 Characterization of hydrophobic anti-cancer drug-loaded amphiphilic peptides as a gene carrier.